Fluvastatin Induces Apoptosis of Vascular Endothelial Cells: Blockade by Glucocorticoids

Vascular

Volumn 11, Issue 1, 2003, Pages 52-60

  Newton, C J ^a   Xie, Y X ^a   Burgoyne, C H ^b   Adams, I ^b   Atkin, S L ^b   Abidia, A ^b   Mccollum, P T ^b  

^a Jacob's Well Med Res Laboratory   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

apoptosis; glucocorticoids; statins

Indexed keywords

ANDROGEN; ANDROSTANOLONE; DEXAMETHASONE; FLUINDOSTATIN; GLUCOCORTICOID;

APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; REDUNDANCY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0037305761     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721090301100110     Document Type: Article

References (33)

1. Grundy, S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. New England Journal of Medicine, 1988, 319, 24-33.
2. Gould, A. L. Rossouw, J. E. Santanello, N. C. et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation, 1998, 97, 946-952.
3. Stark, W. W. Blaskovich, M. A. Johnson, B. A. et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. American Journal of Physiology, 1998, 275, 55-63.
4. Guijarro, C. Blanco-Colio, L. M. Massy, Z. A. et al. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney International Supplement, 1999, 71, 88-91.
5. Buemi, M. Allegra, A. Senatore, M. et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. European Journal of Pharmacology, 1999, 9, 201-203.
6. Edwards, P. A. and Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthesis pathway. Annual Review of Biochemistry, 1999, 68, 157-185.
7. Sinensky, M. Recent advances in the study of prenylated proteins. Biochimica et Biophysica Acta, 2000, 1484, 93-106.
8. Perez-Sala, D. and Mollinedo, F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochemical and Biophysical Research Communications, 1994, 199, 1209-12015.
9. Rowinsky, E. K. Windle, J. J. and VonHoff, D. D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. Journal of Clinical Oncology, 1999, 17, 3631-3652.
10. Sebti, S. M. and Hamilton, A. D. Farnesyltransferase and geran-ylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to beside issues. Expert Opin lnvestig Drugs, 2000, 9, 2767-2782.
11. Perrin, D. and Hill, B. T. Tommorro's anticancer agents: inhibitors of Ras farnesylation. EXS, 2000, 89, 153-179.
12. Garcia-Roman, N. Alvarez, A. M. Toro, M. J. et al. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Molecular and Cellular Neurosciences, 2001, 17, 329-341.
13. Adams, J. M. and Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends in Biochemical Sciences, 2001, 26, 61-66.
14. von Lintig, F. C. Dreilinger, A. D. Varki, N. M. et al. Ras activation in human breast cancer. Breast Cancer Research and Treatment, 2000, 62, 51-62.
15. Baxter, R. C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology, 2001, 54, 145-148.
16. Merritt, J. E. Sullivan, J. A. Tse, J. et al. Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction. Cellular Signalling, 1997, 9, 53-57.
17. Langtry, H. D. and Markham, A. Fluvastatin: a review of its use in lipid disorders. Drugs, 1999, 57, 583-606.
18. Claise, C. Chalas, J. Edeas, M. et al. Comparison of oxidized low density lipoprotein toxicity on EA.hy 926 cells and human vein endothelial cells: influence of antioxidant systems. Cell Mol Life Sci, 1997, 53, 156-161.
19. Ormerod, M. G. Cell cycle analysis of asynchronous population. Methods in Molecular Biology, 1998, 91, 157-165.
20. Newton, C. J. Estrogen receptor blockade by the pure antiestrogens, ZM 182780, induces death of pituitary tumour cells. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 327-336.
21. Newton, C. J. Drummond, N. Burgoyne, C. H. et al. Functional inactivation of the oestrogen receptor by the antioestrogen, ZM 182780, sensitizes tumour cells to reactive oxygen species. Journal of Endocrinology, 2000, 161, 199-210.
22. Speirs, V. Boyle-Walsh, E. and Fraser, W. D. Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. International Journal of Cancer, 1997, 72, 714-719.
23. Newton, C. J. Bilko, D. Pappa, S. et al. Dexamethasone blocks antioestrogen- and oxidant-induced death of pituitary tumour cells. Journal of Endocrinology, 2001, 169, 249-261.
24. Wu, J. R. and Gilbert, D. M. Lovastatin arrests CHO cells between the origin decision point and the restriction point. FEBS Letters, 2000, 3, 108-112.
25. Zhang, H. H. Kumar, S. Barnett, A. H. et al. Dexamethasone inhibits tumour necrosis factor-alpha-induced apoptosis and interleukin-1 beta release in human subcutaneous adipocytes and preadipocytes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2817-2825.
26. Sasson, R. Tajima, K. and Amsterdam, A. Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3′, 5′-monophosphate and p53 activation in immortalized human granulose cells: involvement of Bcl-2. Endocrinology, 2001, 142, 802-811.
27. Mikosz, C. A. Brickley, D. R. Sharkey, M. S. et al. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of serine/threonine survival gene, sgk-1. Journal of Biological Chemistry, 2001, 276, 16649-16654.
28. Messmer, U. K. Pereda-Fernandez, C. Manderscheid, M. et al. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP down regulation in MCF-7 cells. British Journal of Pharmacology, 2001, 133, 467-476.
29. Andersson, C. Lydrup, M. L. Ferno, M. et al. Immunohistoch-emical demonstration of oestrogen receptor beta in blood vessels of female rat, Journal of Endocrinology, 2001, 169, 241-247.
30. Scheidegger, K. J. Cenni, B. Picard, D. et al. Estradiol decreases IGF-1 and IFG-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. Journal of Biological Chemistry, 2000, 275, 38921-38928.
31. Makela, S. Savolainen, H. Avik, E. et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and bete. Proceedings of the National Academy of Sciences, USA, 1999, 8, 7077-7082.
32. Linder, V. Kim, S. K. Karas, R. H. et al. Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circulation Research, 1998, 27, 224-229.
33. Orimo, A. Inoue, S. Ouchi, Y. et al. Vascular smooth muscle cells possess estrogen receptor and respond to estrogen. Annals of the New York Academy of Sciences, 1995, 17, 592-594.